Logo image of KALV

KALVISTA PHARMACEUTICALS INC (KALV) Stock Fundamental Analysis

USA - NASDAQ:KALV - US4834971032 - Common Stock

12.05 USD
-0.13 (-1.07%)
Last: 10/1/2025, 9:05:27 PM
12.05 USD
0 (0%)
After Hours: 10/1/2025, 9:05:27 PM
Fundamental Rating

1

Taking everything into account, KALV scores 1 out of 10 in our fundamental rating. KALV was compared to 536 industry peers in the Biotechnology industry. KALV may be in some trouble as it scores bad on both profitability and health. KALV has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

KALV had negative earnings in the past year.
KALV had a negative operating cash flow in the past year.
In the past 5 years KALV always reported negative net income.
KALV had a negative operating cash flow in each of the past 5 years.
KALV Yearly Net Income VS EBIT VS OCF VS FCFKALV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M -150M

1.2 Ratios

KALV has a Return On Assets of -58.77%. This is comparable to the rest of the industry: KALV outperforms 44.22% of its industry peers.
KALV has a Return On Equity of -310.48%. This is in the lower half of the industry: KALV underperforms 71.64% of its industry peers.
Industry RankSector Rank
ROA -58.77%
ROE -310.48%
ROIC N/A
ROA(3y)-48.3%
ROA(5y)-38.68%
ROE(3y)-54.5%
ROE(5y)-43.24%
ROIC(3y)N/A
ROIC(5y)N/A
KALV Yearly ROA, ROE, ROICKALV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 1K 1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for KALV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KALV Yearly Profit, Operating, Gross MarginsKALV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K -80K

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for KALV has been increased compared to 1 year ago.
KALV has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, KALV has a worse debt to assets ratio.
KALV Yearly Shares OutstandingKALV Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
KALV Yearly Total Debt VS Total AssetsKALV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

KALV has an Altman-Z score of -3.77. This is a bad value and indicates that KALV is not financially healthy and even has some risk of bankruptcy.
KALV's Altman-Z score of -3.77 is in line compared to the rest of the industry. KALV outperforms 44.22% of its industry peers.
KALV has a Debt/Equity ratio of 3.24. This is a high value indicating a heavy dependency on external financing.
KALV has a worse Debt to Equity ratio (3.24) than 81.34% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.24
Debt/FCF N/A
Altman-Z -3.77
ROIC/WACCN/A
WACCN/A
KALV Yearly LT Debt VS Equity VS FCFKALV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

KALV has a Current Ratio of 5.37. This indicates that KALV is financially healthy and has no problem in meeting its short term obligations.
KALV has a Current ratio of 5.37. This is comparable to the rest of the industry: KALV outperforms 58.77% of its industry peers.
KALV has a Quick Ratio of 5.37. This indicates that KALV is financially healthy and has no problem in meeting its short term obligations.
KALV's Quick ratio of 5.37 is in line compared to the rest of the industry. KALV outperforms 59.89% of its industry peers.
Industry RankSector Rank
Current Ratio 5.37
Quick Ratio 5.37
KALV Yearly Current Assets VS Current LiabilitesKALV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for KALV have decreased by -7.65% in the last year.
EPS 1Y (TTM)-7.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 19.82% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-6.1%
EPS Next 2Y-4.04%
EPS Next 3Y16.31%
EPS Next 5Y19.82%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KALV Yearly Revenue VS EstimatesKALV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
KALV Yearly EPS VS EstimatesKALV Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KALV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KALV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KALV Price Earnings VS Forward Price EarningsKALV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KALV Per share dataKALV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

KALV's earnings are expected to grow with 16.31% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.04%
EPS Next 3Y16.31%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KALV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KALVISTA PHARMACEUTICALS INC

NASDAQ:KALV (10/1/2025, 9:05:27 PM)

After market: 12.05 0 (0%)

12.05

-0.13 (-1.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-11 2025-09-11/bmo
Earnings (Next)12-03 2025-12-03
Inst Owners102.5%
Inst Owner Change-0.89%
Ins Owners1.45%
Ins Owner Change16.54%
Market Cap606.60M
Analysts86.25
Price Target32.3 (168.05%)
Short Float %24.85%
Short Ratio11.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-19.72%
Min EPS beat(2)-24.26%
Max EPS beat(2)-15.18%
EPS beat(4)2
Avg EPS beat(4)-6.3%
Min EPS beat(4)-24.26%
Max EPS beat(4)12.51%
EPS beat(8)4
Avg EPS beat(8)-7.78%
EPS beat(12)8
Avg EPS beat(12)1.22%
EPS beat(16)12
Avg EPS beat(16)2.57%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)16.21%
EPS NQ rev (1m)-10.28%
EPS NQ rev (3m)-36.53%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.22%
Revenue NQ rev (1m)10.46%
Revenue NQ rev (3m)-44.58%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 14.87
P/tB 14.87
EV/EBITDA N/A
EPS(TTM)-3.8
EYN/A
EPS(NY)-3.68
Fwd EYN/A
FCF(TTM)-3.35
FCFYN/A
OCF(TTM)-3.32
OCFYN/A
SpS0
BVpS0.81
TBVpS0.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -58.77%
ROE -310.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.3%
ROA(5y)-38.68%
ROE(3y)-54.5%
ROE(5y)-43.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 3.24
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 132.2%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.37
Quick Ratio 5.37
Altman-Z -3.77
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)129.01%
Cap/Depr(5y)89%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.74%
EPS Next Y-6.1%
EPS Next 2Y-4.04%
EPS Next 3Y16.31%
EPS Next 5Y19.82%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-26.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-46.84%
EBIT Next 3Y-7.69%
EBIT Next 5YN/A
FCF growth 1Y-98.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-101.12%
OCF growth 3YN/A
OCF growth 5YN/A